FIGURE 1.

Covariate effects on pharmacokinetic parameters of infliximab (estimated with the full covariate model) relative to the reference subject (70 kg, 32 years at diagnosis, Crohn's disease, no concomitant corticosteroids or immunomodulators, albumin 44 g/L, white blood cell count 7.1 × 10⁹/L, platelet count 295 × 10⁹/L, no anti‐drug antibodies). An effect greater than ±20% was considered clinically important. The point estimate with 95% bootstrapped confidence intervals is depicted. Abbreviations: ADA, anti‐drug antibodies; Q, intercompartmental clearance; SC, subcutaneous; V_c, volume of distribution in the central compartment; V_p, volume of distribution in the peripheral compartment [Colour figure can be viewed at wileyonlinelibrary.com]